A landmark study from Sweden, published in The BMJ, confirmed the long-term efficacy of the Human Papillomavirus (HPV) vaccine. This research provides the strongest evidence of its sustained protection” against invasive cervical cancer, with no signs of waning immunity.
These findings will bolster global public health strategies aimed at eliminating cervical cancer.
The Challenge of Long-Term Immunity
Persistent infection with high-risk HPV types is the primary contributor to invasive cervical cancer. While HPV vaccination has been a cornerstone of global efforts to eliminate this disease for over two decades, scientific evidence regarding its long-term efficacy remains limited.
A key question for clinicians and policymakers is whether the protection offered in adolescence remains robust as women move into their 30s and 40s—when the cervical cancer risk heightens.
To address this, researchers utilised Sweden’s comprehensive nationwide registries to track the health outcomes of nearly one million women. The study evaluated the risk of invasive cervical cancer in those who received the quadrivalent HPV vaccine compared to those who remained unvaccinated.
Study Methodology
The research team followed 926,362 girls and women born between 1985 and 2001 over an 18-year period (2006–2023). Participants were followed up to a maximum age of 38 – to evaluate the vaccine’s real-world performance over two decades. Women were categorised into four distinct cohorts based on the nature of the vaccination programme available to them:
- Opportunistic Cohort (born 1985–88): Self-funded vaccination
- Subsidised Cohort (born 1989–92): Government-subsidised initiatives
- Catch-up Cohort (born 1993–98): Parallel programmes for school-aged pupils
- School-based Cohort (born 1999–2001): Routine, free-of-charge vaccination delivered via school health infrastructure
The analysis accounted for various contributing factors, including:
- County of residence and parental income
- Level of parental education
- Mother’s country of birth
- Previous history of non-cervical cancers or high-grade lesions
Key Findings: The Importance of Early Vaccination
Of the total participants, 40% received at least one dose of the quadrivalent vaccine. During the follow-up period, 930 invasive cervical cancer cases were identified. Among these, 833 occurred in unvaccinated women, compared to just 97 in the vaccinated group.
The data revealed a stark difference in outcomes between the two groups. Further, the age at which a person was vaccinated played a crucial role in the level of protection achieved. Those vaccinated before the age of 17 experienced the most significant benefits.
Comparative Risk Reduction of Invasive Cervical Cancer:
| Group | Risk Reduction (%) | Long-term Stability (13–15 Years) |
| Vaccinated < Age 17 | 79% Lower Risk | 77% Lower Risk |
| Vaccinated > Age 17 | 37% Lower Risk | 77% Lower Risk* |
Evidence of Sustained Protection
The results revealed that early vaccination rendered a remarkably stable protection.
Notably, there was no indication of waning or attenuation of immunity over time.
For girls vaccinated between the ages of 10 and 16, the incidence rate ratios (IRRs) remained consistently low throughout the follow-up period. The IRR was 0.24 and 0.23 at 13–15 years and at 7–9 years post-vaccination, respectively.
For those vaccinated later in life (at 17 years of age or older), the benefit became more apparent over a longer span. While no significant protection was evident during the first nine years—likely due to pre-existing HPV exposure—a significant risk reduction was recorded during years 10–12 (IRR 0.54) and 13–15 (IRR 0.23), after vaccination.
At 15 years post-vaccination, the risk of developing invasive cervical cancer remained approximately 77% lower in the vaccinated groups.
The results attest that the vaccine’s prophylactic benefits remain clinically vital even when administered during adulthood.
A Population-Level Decline
Besides individual protection, the study highlights a dramatic shift in cervical cancer rates across different generations. Women born between 1985 and 1988, who reached adulthood before vaccination programmes, saw cervical cancer incidence rates of approximately 250 cases per 100,000 by age 38.
In contrast, for the cohort born between 1999 and 2001, who had the highest access to routine immunisation, the rate plummeted to 4 cases per 100,000 by age 24.
The school-based cohort achieved the highest vaccine uptake (76.2%) and the youngest median age at vaccination (12.2 years). This group showed a 72% lower risk of cervical cancer compared to the opportunistic cohort. The outcomes reaffirm the success of organised, national immunisation strategies.
The clinical impact of this research is two-fold:
- The data reinforce current global strategies that prioritise vaccination at a young age through school-based programmes.
- The delayed observation of risk reduction in older cohorts highlights the need for extended follow-up (longer than a decade) to accurately evaluate the effectiveness of vaccination initiatives.
Global Implications for Cancer Elimination
This 18-year follow-up data provides the first clinical confirmation that the quadrivalent HPV vaccine offers durable, long-term protection against invasive cervical cancer with no loss of efficacy over time. The vaccination programmes significantly reduced the chronic low-grade infection that causes cervical malignancy and represent a pivotal advancement in public health.
By achieving high coverage in younger populations, healthcare systems can effectively neutralise one of the most common causes of cancer-related deaths in women.
The findings offer healthcare professionals and policymakers the evidence needed to continue advocating for high vaccine coverage as a primary tool for the global elimination of cervical cancer. As nations continue to refine their immunisation strategies, this Swedish data is a powerful reminder that early intervention provides a lifetime of security.
Keywords: HPV vaccination, cervical cancer prevention, sustained protection, quadrivalent HPV vaccine, The BMJ study, clinical impact, school-based vaccination, invasive cervical cancer, routine immunisation programmes, public health data.
Suggested Reads:
https://www.bmj.com/content/392/bmj-2025-087326
chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/http://press.psprings.co.uk/bmj/february/cervicalcancer.pdf
chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/http://press.psprings.co.uk/AMSlabels.pdf
